AbstractObtaining opioids from multiple prescribers, known as doctor shopping, is 1 example of opioid abuse and diversion. The dual mechanism of action of tapentadol could make tapentadol less likely to be abused than other opioids. The aim of this retrospective cohort study was to compare the risk of shopping behavior between tapentadol immediate release (IR) and oxycodone IR. Subjects exposed to tapentadol or oxycodone with no recent opioid use were included and followed for 1 year. The primary outcome was the proportion of subjects who developed shopping behavior defined as subjects who had opioid prescriptions written by >1 prescriber with ≥1 day of overlap filled at ≥3 pharmacies. The opioids involved in the shopping episodes were asse...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...
It is estimated that nearly a third of people who abuse drugs started with prescription opioid medic...
Background: There is increasing concern about tampering of pharmaceutical opioids. We describe early...
Objectives: This study compared the risks of opioid shopping behavior and opioid abuse between tapen...
AbstractTapentadol may have a lower abuse risk than other opioids because it has a relatively low af...
AbstractBackgroundDoctor-shopping (obtaining prescriptions from multiple prescribers/pharmacies) for...
Abuse of prescription opioid analgesics is a serious threat to public health, resulting in rising nu...
Background: Abuse of prescription opioid analgesics is a serious threat to public health, resulting ...
Objective: To characterize the use of tapentadol and the combination oxycodone/naloxone in primary h...
Background: The rapid increase in prescribing and use of opioids for noncancer pain has coincided wi...
Introduction:It has been argued that tapentadol may pharmacologically have lower abuse potential tha...
Introduction and aims Extramedical use of, and associated harms with pharmaceutical opioids are comm...
Aims: A sustained-release formulation (SRF) of tapentadol has been marketed in Australia since Febru...
Background: Escalation of pharmaceutical opioid use and harm in North America is well-documented, wi...
Aims: A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...
It is estimated that nearly a third of people who abuse drugs started with prescription opioid medic...
Background: There is increasing concern about tampering of pharmaceutical opioids. We describe early...
Objectives: This study compared the risks of opioid shopping behavior and opioid abuse between tapen...
AbstractTapentadol may have a lower abuse risk than other opioids because it has a relatively low af...
AbstractBackgroundDoctor-shopping (obtaining prescriptions from multiple prescribers/pharmacies) for...
Abuse of prescription opioid analgesics is a serious threat to public health, resulting in rising nu...
Background: Abuse of prescription opioid analgesics is a serious threat to public health, resulting ...
Objective: To characterize the use of tapentadol and the combination oxycodone/naloxone in primary h...
Background: The rapid increase in prescribing and use of opioids for noncancer pain has coincided wi...
Introduction:It has been argued that tapentadol may pharmacologically have lower abuse potential tha...
Introduction and aims Extramedical use of, and associated harms with pharmaceutical opioids are comm...
Aims: A sustained-release formulation (SRF) of tapentadol has been marketed in Australia since Febru...
Background: Escalation of pharmaceutical opioid use and harm in North America is well-documented, wi...
Aims: A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It...
Aim: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone a...
It is estimated that nearly a third of people who abuse drugs started with prescription opioid medic...
Background: There is increasing concern about tampering of pharmaceutical opioids. We describe early...